APA (7th ed.) Citation

Heinemann, V., Vehling-Kaiser, U., Waldschmidt, D., Kettner, E., Märten, A., Winkelmann, C., . . . Boeck, S. (2013). Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: Final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104). Gut, 62(5), 751-759. https://doi.org/10.1136/gutjnl-2012-302759

Chicago Style (17th ed.) Citation

Heinemann, Volker, et al. "Gemcitabine Plus Erlotinib Followed by Capecitabine Versus Capecitabine Plus Erlotinib Followed by Gemcitabine in Advanced Pancreatic Cancer: Final Results of a Randomised Phase 3 Trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)." Gut 62, no. 5 (2013): 751-759. https://doi.org/10.1136/gutjnl-2012-302759.

MLA (9th ed.) Citation

Heinemann, Volker, et al. "Gemcitabine Plus Erlotinib Followed by Capecitabine Versus Capecitabine Plus Erlotinib Followed by Gemcitabine in Advanced Pancreatic Cancer: Final Results of a Randomised Phase 3 Trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)." Gut, vol. 62, no. 5, 2013, pp. 751-759, https://doi.org/10.1136/gutjnl-2012-302759.